Skip to main content

Table 2 Population estimates of the base and the final model for AS/DHA

From: Fixed dose artesunate amodiaquine – a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine

  Base model Final model
Parameter Mean Standard error Mean Standard error
KaAS(h−1) 2.45 0.34 2.41 0.34
CL/FAS (L/h) 797 102 616 98.4
V/FAS(L) 119 51.8 85.2 36.0
FM(%) 0.81 0.16 0.00781 0.00108
Kem (h−1) 0.819 0.266 0.742 0.166
ѲBWkem NA NA 1.65 0.46
ѲFORM NA NA 1.79 0.36
ω2CL/FAS 0.101 0.089 NE NE
ω2V/FAS 1.94 2.23 2.21 2.27
ω2kemDHA 0.000352 0.0666 NE NE
σ2adAS 0.000218 0.000122 0.000277 0.00015
σ2multAS 0.665 0.154 0.674 0.116
σ2adDHA 0.0438 0.0299 0.0324 0.0223
σ2multDHA 0.391 0.093 0.374 0.0726
  1. KaAS: absorption rate constant of AS, CL/FAS: apparent clearance of AS, V/FAS: apparent distribution volume of AS, FM: fraction of AS metabolized into DHA, K34 and K43: distribution rate constants of DAQ, Kem: elimination rate constant of DHA, ѲBWkm: influential factor of BW on DHA kem, ѲFORM : influence of dosage form on AS bioavailability, ω2CL/FAS: interindividual variability of CL/FAS, ω2V/FAS: interindividual variability of V/FAS, σ2multAS: proportional residual error for AS, σ2adAS: additive residual error for AS , σ2multDHA: proportional residual error for DHA, σ2adDHA: additive residual error for DHA, NA: Not Available, NE: Not Estimated.
\